Evaluated for: Wet macular degeneration
How it works: Retaane (anecortave) is an investigational drug marketed by Alcon Labs. The drug is administered behind the eye using a blunt-tipped, curved tube. Because the tube does not puncture the eye, the procedure reduces the risks associated with the injection of compounds directly into the eye including infection inside the eye or retinal detachment. An added benefit is that Retaane is usually given only once every six months, in comparison with some other experimental drugs which must be injected into the eye almost on a monthly basis. The drug acts as an anti-angiogenic agent, meaning that it blocks the growth of abnormal blood vessels.
Most common side effects: No adverse side effects have yet been reported; however, this experimental drug is still in clinical trials.
A thoughtful evaluation must be performed by a physician before taking any medications, over-the-counter drugs, supplements, or herbs. The American Health Assistance Foundation does not endorse any of these medications, vitamins, or herbs. A qualified physician should make an informed decision based on each person's medical history and current prescriptions. The medication summaries provided do not include all of the information important for patient use and should not be used as a substitute for professional medical advice. The prescribing physician should be consulted concerning any questions that you have.
The information provided in this section of our website was obtained from the National Institutes of Health (NIH)/National Eye institute (NEI), the Food and Drug Administration (FDA), the National Library of Medicine, and research scientists specializing in macular degeneration.
Reviewed on 2/14/2008